Principal Investigator
Jonathan Trent
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231415
Clinical Trial Summary
An International, Phase 3, Randomized, Multicenter, Open-label
Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Bone and Soft Tissue Cancers
Contact Information
Phone Number
305-243-2647